Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults.
The Centers for Disease Control and Prevention convened panels of anthrax experts to review and update guidelines for anthrax postexposure prophylaxis and treatment. The panels included civilian and military anthrax experts and clinicians with experience treating anthrax patients. Specialties represented included internal medicine, pediatrics, obstetrics, infectious disease, emergency medicine, critical care, pulmonology, hematology, and nephrology. Panelists discussed recent patients with systemic anthrax; reviews of published, unpublished, and proprietary data regarding antimicrobial drugs and anthrax antitoxins; and critical care measures of potential benefit to patients with anthrax. This article updates antimicrobial postexposure prophylaxis and antimicrobial and antitoxin treatment options and describes potentially beneficial critical care measures for persons with anthrax, including clinical procedures for infected nonpregnant adults. Changes from previous guidelines include an expanded discussion of critical care and clinical procedures and additional antimicrobial choices, including preferred antimicrobial drug treatment for possible anthrax meningitis.
Katherine A
KA
Hendricks
Mary E
ME
Wright
Sean V
SV
Shadomy
John S
JS
Bradley
Meredith G
MG
Morrow
Andy T
AT
Pavia
Ethan
E
Rubinstein
Jon-Erik C
JE
Holty
Nancy E
NE
Messonnier
Theresa L
TL
Smith
Nicki
N
Pesik
Tracee A
TA
Treadwell
William A
WA
Bower
D000328:Adult; D000881:Anthrax / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D022122:Anthrax Vaccines / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000992:Antitoxins / Q000627:therapeutic use; D001408:Bacillus anthracis / Q000187:drug effects / Q000276:immunology / Q000472:pathogenicity*; D023482:Bioterrorism; D002487:Centers for Disease Control and Prevention, U.S.; D002983:Clinical Competence; D003422:Critical Care; D019468:Disease Management; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D014481:United States
D022122:Anthrax Vaccines; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000992:Antitoxins; D016756:Immunoglobulins, Intravenous; C542124:raxibacumab
Bacillus anthracis; Centers for Disease Control and Prevention; adults; anthrax; antitoxin; bacteria; bioterrorism and preparedness; expert panel meeting; prevention; raxibacumab; treatment